TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: L(2-4) BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of vaginal birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Response rate (Y-BOCS score decrease ≥25%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving minimal symptoms (Y-BOCS score ≤12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation and cessation of douching
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gastric mucosa lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Severe gastric lesions (grades 3 and 4)
Endpoint domain: Adverse events/effects
Primary endpoint: AUC(0‐t) of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma linezolid concentrations above MIC90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Management Scale (SDSCA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Center for Epidemiologic Studies Depression Scale (CES-D-10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acquisition of Trichomonas vaginalis (TV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HP negative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of angina attacks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Asthma Quality of Life Questionnaire (AQLQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Relief of daytime and nighttime asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: technical performance postintervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle postoperative function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical length change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Sympathetic Activity (MSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catecholamine plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum deviations in eye abduction and depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal and vertical ocular motility reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-program symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived benefits
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in relative [Formula: see text] values between PRETmax and RAMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total DRSP score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: H(+) secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Volume of gastric aspirate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pH of gastric aspirate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in pain associated with dressing changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tear Break-Up Time (BUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rose Bengal Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: de novo plaque formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective ratings for taste
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PBI and BOP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haematoma growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean incremental test duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean endurance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastric content volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Circulating proinflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating anti-inflammatory IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monocyte surface expression of HLA-DR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 30% PANSS responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal and Social Performance scale scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Clinical efficacy on MPS of the back
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sick visits by 1 month
Endpoint domain: Adverse events/effects
Primary endpoint: Functional assessment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bilateral polyp grade score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in congestion/obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall effectiveness over one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) or response (R) criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral midazolam clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral simvastatin clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient rating of outcome (excellent, good, fair)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of secondary osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postoperative FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: global psychopathological state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction at work
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aspiration of gastric contents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in total low-density lipoprotein (LDL) particle concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in total very low-density lipoprotein (VLDL) particle concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in total high-density lipoprotein (HDL) particle concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neutralizing antibodies to vaccinia virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Binding antibodies to whole virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell immune responses to vaccinia virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recovery time to normal performance on serial reaction time (SRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time to normal performance on logical reasoning (LRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time to normal performance on multitask (MT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) of the spine and hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in baseline wart area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: overall optimal glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean capillary glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in synechial angle closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in angle-opening distance (AOD500)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in anterior chamber depth (ACD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anal sphincter tone (MARP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary iodine status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving sUA < 5.0 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving sUA < 6.0 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of gout flare
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative annual incidence of hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of POCD
Endpoint domain: Adverse events/effects
Primary endpoint: Level of serum S-100beta protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clearance of HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurodevelopmental impairment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cognitive score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HIV progression
Endpoint domain: Mortality/survival
Primary endpoint: virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants achieving two or more consecutive weeks of abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tinnitus total score on the Tinnitus Handicap Inventory (THI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tinnitus total score on the Tinnitus Questionnaire (TQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue pain score during coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction of systolic arterial pressure from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient satisfaction with the analgesia technique
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients in sinus rhythm at long-term follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cure or improvement of VVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global symptom scores (GSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total money earned
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite end point of death or MI
Endpoint domain: Mortality/survival
Primary endpoint: within-person variability of mood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: within-person variability of energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: within-person variability of speed of thoughts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of significant prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Risk prediction for any prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk prediction for significant prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: readiness to leave the abuser
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: K‐ras mutations identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic correlation between MD and AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reinforcement value of cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotational stability during walking, running, and pivoting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall abstinence at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ICD-10 CMD diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion of persistent atrial fibrillation (AFF) at 36 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Docosahexaenoic acid concentrations in red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Arachidonic acid concentrations in red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: National Institutes of Stroke Scale score on admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay between symptom recognition and hospital arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of aphasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amprenavir trough concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in maxillary arch width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in mandibular arch perimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the memory subscale of the Dementia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: b-wave amplitudes of the mf-ERG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of delayed graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: rate of rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PGE2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sleep disturbed because of wheezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: No bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient rating of dressings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nurse rating of ease of assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative incidence of ulcers > or =3 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dysphonia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average AUC for part-solid nodule detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the size of the affected area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Daytime asthma symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in end-systolic volume (ESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in end-diastolic volume (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Pulmonary Infection Score (CPIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumothorax rate
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in haemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of anaemia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood perfusion at the myocardial tissue level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bicarbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in diagnosis of polyps and submucous myomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of UCROM measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPSS mean change from baseline to end point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of non-vertebral fractures
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of supine position for sleeping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: memory vividness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: memory emotionality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in trait anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in anger expression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hands-off interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with A1c less than 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion with annual eye exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CGMG (days 1-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time in target glycaemic range (70-180 mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time CGMG > 180 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients no longer having gupt rog problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported sex with a partner who was not the wife
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improvement in educational experience with evidence based medicine
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Increased confidence in clinical decision making
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IUK:Cr ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Psychopathology vulnerability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urinary LT-E4 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urinary PG-F2a levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Static pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Use of intravenous antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cross section of the nasal cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum epinephrine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global QoR‐15 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average power values for IR muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes